6-K ·Filed Apr 27, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Routine scientific conference presentation with no material financial impact. Monitor for potential partnership or clinical advancement of the epigenetic platform, but no immediate trading catalyst.
Final — all horizons settled through T+60d
CLLS ▼ -30.75% at T+60d
NEUTRAL call -30.75% · α vs SPY -34.74% · entry $4.00 → $2.77
T+1d
-5.70%
call -5.70% · α -5.69%
$3.77
settled 6mo ago
T+5d
-7.50%
call -7.50% · α -9.19%
$3.70
settled 6mo ago
T+20d
-8.25%
call -8.25% · α -13.72%
$3.67
settled 5mo ago
T+60d
-30.75%
call -30.75% · α -34.74%
$2.77
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Cellectis announced preclinical data on its TALE-based epigenetic editing platform (TALEM) at the ASGCT annual meeting, achieving >90% sustained gene knockdown in two targets without DNA breaks. This is an early-stage research update with no immediate financial or regulatory implications.
Key Facts
- TALEM epigenetic editors achieved >90% reduction in gene activity in hepatocytes and T-cells
- No DNA breaks or sequence modifications required
- Poster presentation at ASGCT on May 13, 2026
- Preclinical data; not yet in clinical trials for this platform
Financial Impact
No financial data provided in this filing
Risk Factors
- Epigenetic editing remains early-stage with no clinical validation
- Cellectis primarily focused on CAR-T therapies; this platform may not advance
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
85% bullish (13 analysts)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002734 |
| Document: f6k_042726.htm | 0001171843-26-002734 |
| Document: 0001171843-26-002734-index-headers.html | 0001171843-26-002734 |
| Document: 0001171843-26-002734-index.html | 0001171843-26-002734 |
| Document: 0001171843-26-002734.txt | 0001171843-26-002734 |
14 reports for CLLS
40% Hit rate @ T+60 Went positive at some point 4 of 6 best @ T+20▲ +35.52%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 6-K | $1.83 | awaiting T+60 | — | $0.9670 (+47.16%) |
Sep 11, 2026 6w ago | Press Release | $1.83 | awaiting T+60 | — | $0.9670 (−47.16%) |
Aug 6, 2026 11w ago | Press Release | $2.84 | awaiting T+60 | — | $0.9670 (−65.89%) |
Jun 29, 2026 17w ago | Court Ruling | $3.00 $1.43 | ▼ −52.33% | ▼ −55.32% | $0.9670 (−67.77%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9670 (−65.83%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9670 (−65.83%) |
Jun 11, 2026 19w ago | Press Release | $3.09 $3.24 | ▲ +4.85% | ▲ +0.46% | $0.9670 (−68.71%) |
Jun 9, 2026 19w ago | 6-K | $3.18 $3.32 | ▲ +4.40% | ▼ −2.18% | $0.9670 (−69.59%) |
May 12, 2026 23w ago | 6-K | $3.96 $2.69 | ▼ −32.07% | ▼ −36.45% | $0.9670 (−75.58%) |
May 4, 2026 25w ago | 6-K | $3.76 $2.85 | ▼ −24.20% | ▼ −26.94% | $0.9670 (−74.28%) |
Showing 10 of 14
US Market Status
Market Closed — Opens in 2h 31m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers